MGAT3 and myelodysplastic syndrome: reported lower GnT-III levels and bisecting GlcNAc on bone marrow stroma in myelodysplastic syndrome and acute myeloid leukemia patients compared to healthy donors (62), further suggesting GnT-III as a potential target associated with the ERK pathway in differentiation therapy.